PTSM: Pharmaceutical Technology Sourcing and Management
FDA completes an inspection of Cambrex's API manufacturing facility in Charles City, Iowa.
Cambrex reported that FDA completed an inspection of Cambrex’s API manufacturing facility in Charles City, Iowa. The inspection found the site to be compliant with the principles and guidelines of GMP and no Form 483 observations were issued. FDA authorities inspected the facility from July 31 to August 2, 2013.
This follows successful inspections at Charles City made previously by FDA in March 2010 and February 2012, neither of which resulted in any issued 483 observations, the Korean FDA in January 2012 and the Medicines and Healthcare Products Regulatory Agency of the UK October 2011, after which a GMP certificate for a drug product intermediate was issued.
Source: Cambrex
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.